By Onkar B. Sawant, PhD, Vice President, Research & Development
In the world of ocular surface reconstruction, advancements are crucial for improving the lives of patients suffering from often painful and complex eye disease. One such breakthrough is Eversight’s launch of KLAL-Pro, a cutting-edge, eye-bank prepared tissue for the treatment of limbal stem cell deficiency (LSCD). As we continue to innovate in eye banking, KLAL-Pro offers a quality-controlled option for surgeons seeking to treat unilateral or bilateral LSCD.
What is KLAL-Pro?
How does KLAL-Pro work?
KLAL-Pro is prepared to meet the specific needs of each patient. The tissue is available in 3-4mm anteroposterior thickness, up to 180 degrees of donor limbus per segment, and approximately 200-300µm thick. KLAL-Pro supports ocular surface reconstruction and serves as an essential treatment for both unilateral and bilateral LSCD.
When transplanted, KLAL-Pro's regenerative properties promote limbal stem cell expansion, aiding in the repair of damaged ocular surfaces and significantly improving visual outcomes. Early clinical use has shown that this allograft enhances results from both traditional keratolimbal allograft (KLA) and modified Cincinnati procedures. With its regenerative capabilities, KLAL-Pro has proven to be a valuable tool for addressing bilateral and unilateral LSCD—providing patients with hope for vision restoration.
Why choose KLAL-Pro?
For ophthalmologists, finding an effective treatment for bilateral and unilateral LSCD can be challenging as there may not be enough viable autograft stem cells. KLAL-Pro has shown promise as a durable, regenerative treatment option, offering a new level of support for patients whose vision may have been otherwise irreparable. The benefits of KLAL-Pro go beyond just improving visual acuity—it can be an essential tool for improving quality of life and long-term ocular health.
In early clinical applications, KLAL-Pro has demonstrated:
- Limbal stem cell expansion and re-epithelization
- Improved visual outcomes, enhancing the patient’s functional vision and eye health
- Durability and regenerative potential, offering long-term treatment benefits for patients with LSCD
What surgeons are saying
“KLAL-Pro grafts minimize excess stromal tissue and streamline the process of ocular surface stem cell transplantation. With appropriate immunosuppression regimens, my patients have had excellent outcomes with KLAL-Pro tissue. KLAL-Pro has already become a key part of my approach to treating limbal stem cell deficiency.”
KLAL-Pro: Ready for your advanced LSCD patients
At Eversight, we want to empower surgeons with the tools they need to restore sight and transform lives. KLAL-Pro is designed to be a high-quality solution that directly addresses the unique challenges posed by LSCD. Whether you’re dealing with unilateral or bilateral LSCD, KLAL-Pro is a game-changer in the pursuit of better patient outcomes.
If you’re ready to take the next step in ocular surface reconstruction or LSCD treatment, Eversight is here to support you every step of the way. KLAL-Pro is now available by request, and we are committed to ensuring timely tissue delivery to meet your needs.
Place your order for KLAL-Pro today and see the difference it can make for your patients.
About Eversight
Eversight is a global nonprofit eye bank dedicated to restoring sight and preventing blindness. We provide eye tissue for transplantation, research, and education, supporting surgeons, researchers, and healthcare professionals worldwide in their pursuit of sight-restoring care.
Let us help you provide the best solutions for your patients.
